ArticleNeurochemical research2025
Saracatinib Promotes Hippocampal Myelin Regeneration and Oligodendrocyte Precursor Cell Maturation by Inhibiting the NOTCH1 Signaling Pathway in Epileptic Mice.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Epilepsy is a common neurological disorder often accompanied by hippocampal myelin damage and impaired differentiation of oligodendrocyte precursor cells (OPCs). This study aimed to investigate the regulatory effects of Saracatinib on myelin regeneration and OPC maturation in a mouse model of epilepsy, as well as its underlying mechanisms, to provide new strategies for the treatment of epilepsy-related myelin damage. Changes in hippocampal myelin structure were observed using Fast Blue staining and transmission electron microscopy. Immunofluorescence was used to detect the number of oligodendrocyte precursor cell (OPCs, PDGFRα) and mature oligodendrocytes (ODCs, MBP+). Cell culture experiments verified the effects of Saracatinib on OPC differentiation, and SwissTargetPrediction and GSEA were used to predict its targets. Western blot and immunofluorescence further validated the role of the NOTCH1 signaling pathway in Saracatinib-mediated OPC differentiation. Saracatinib Reduced the Racine Score, Prolonged Seizure Latency, and Decreased Seizure Duration in an Epileptic Mouse Model. Epileptic model mice exhibited significant hippocampal myelin damage, characterized by thinning of myelin sheaths, reduced myelin quantity, and increased axonal exposure. Saracatinib treatment significantly improved myelin structure, restored myelin thickness and continuity, and alleviated axonal atrophy. Immunofluorescence showed that Saracatinib increased MBP expression and decreased PDGFRα expression, promoting the differentiation of OPCs into ODCs. Bioinformatics analysis and experimental validation demonstrated that Saracatinib promoted OPC maturation by inhibiting the NOTCH1 signaling pathway, and this effect could be reversed by the NOTCH1 agonist JAG1. Saracatinib significantly promotes hippocampal myelin regeneration and OPC maturation in epileptic mice by inhibiting the NOTCH1 signaling pathway, providing a potential molecular target and therapeutic strategy for the treatment of epilepsy-related myelin damage.
Indexed as
Identifiers
41364203What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.